JP2009102341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009102341A5 JP2009102341A5 JP2008309431A JP2008309431A JP2009102341A5 JP 2009102341 A5 JP2009102341 A5 JP 2009102341A5 JP 2008309431 A JP2008309431 A JP 2008309431A JP 2008309431 A JP2008309431 A JP 2008309431A JP 2009102341 A5 JP2009102341 A5 JP 2009102341A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- rapamycin
- hydroxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000003826 tablet Substances 0.000 claims 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 239000007962 solid dispersion Substances 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000007919 dispersible tablet Substances 0.000 claims 2
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Claims (7)
- ４０−Ｏ−（２−ヒドロキシ）エチル−ラパマイシンの固体分散体、架橋ポリビニルピロリドンを含んでなる崩壊剤およびコロイド状二酸化ケイ素を含む医薬組成物であって、１〜５重量％のコロイド状二酸化ケイ素を含んでなる、分散可能な錠剤の形態である医薬組成物。
- 架橋ポリビニルピロリドンが、医薬組成物の総重量に基づき１０〜３０重量％の量で含まれる、請求項１に記載の医薬組成物。
- 錠剤が３５〜８０Ｎの硬度および３分以下の崩壊時間を有する、請求項１または２に記載の医薬組成物。
- 錠剤が９０秒もしくはそれ未満の崩壊時間を有する、請求項３に記載の医薬組成物。
- 錠剤が、２５０ｍｇの組成物を９ｍｍのダイおよび標準的フラットパンチで８〜１１ｋＮの力を用いて圧縮することにより形成されたものである、請求項１〜４のいずれかに記載の医薬組成物。
- 免疫抑制剤として使用するための、請求項１〜５のいずれかに記載の医薬組成物。
- ４０−Ｏ−（２−ヒドロキシ）エチル−ラパマイシン含有分散可能な錠剤の製造方法であって、４０−Ｏ−（２−ヒドロキシ）エチル−ラパマイシンの固体分散体を調製すること、４０−Ｏ−（２−ヒドロキシ）エチル−ラパマイシンの固体分散体を、架橋ポリビニルピロリドンを含んでなる崩壊剤およびコロイド状二酸化ケイ素と混合して医薬組成物を形成させること、ならびに該医薬組成物を圧縮して分散可能な錠剤を形成させることを含んでなる方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0123400.4 | 2001-09-28 | ||
| GBGB0123400.4A GB0123400D0 (en) | 2001-09-28 | 2001-09-28 | Organic compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Division JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009102341A JP2009102341A (ja) | 2009-05-14 |
| JP2009102341A5 true JP2009102341A5 (ja) | 2011-12-08 |
| JP5160386B2 JP5160386B2 (ja) | 2013-03-13 |
Family
ID=9922916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Withdrawn JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
| JP2008309431A Expired - Lifetime JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Withdrawn JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US20040254210A1 (ja) |
| EP (2) | EP1432408B8 (ja) |
| JP (2) | JP2005507897A (ja) |
| KR (1) | KR100626785B1 (ja) |
| CN (3) | CN1951390B (ja) |
| AR (2) | AR036643A1 (ja) |
| AT (1) | ATE485813T1 (ja) |
| BR (2) | BR0212922A (ja) |
| CA (1) | CA2458455C (ja) |
| CO (1) | CO5390072A1 (ja) |
| CY (2) | CY1111119T1 (ja) |
| DE (1) | DE60238131D1 (ja) |
| DK (2) | DK1432408T3 (ja) |
| EC (1) | ECSP024323A (ja) |
| ES (2) | ES2560106T3 (ja) |
| GB (1) | GB0123400D0 (ja) |
| HK (2) | HK1141239A1 (ja) |
| HU (1) | HU229991B1 (ja) |
| IL (2) | IL160498A0 (ja) |
| MX (1) | MXPA04002814A (ja) |
| MY (1) | MY150060A (ja) |
| NO (1) | NO333892B1 (ja) |
| NZ (2) | NZ542273A (ja) |
| PE (1) | PE20030602A1 (ja) |
| PL (1) | PL209704B1 (ja) |
| PT (2) | PT2193788E (ja) |
| RU (1) | RU2322970C2 (ja) |
| SI (1) | SI1432408T1 (ja) |
| TW (1) | TWI242449B (ja) |
| WO (1) | WO2003028705A1 (ja) |
| ZA (1) | ZA200401300B (ja) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| CA2472341C (en) | 2002-02-01 | 2011-06-21 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds & uses thereof |
| DE60324609D1 (de) * | 2002-09-17 | 2008-12-18 | Wyeth Corp | GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779 |
| WO2004035089A1 (ja) * | 2002-10-09 | 2004-04-29 | Kyowa Hakko Kogyo Co., Ltd. | ホルモン依存性癌の治療剤 |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| US8133483B2 (en) * | 2005-06-09 | 2012-03-13 | Hansa Medical Ab | Method of treating or preventing a disease or condition mediated by pathogenic IgG antibodies |
| CN103330694A (zh) * | 2006-11-14 | 2013-10-02 | 阿里亚德医药股份有限公司 | 口服制剂 |
| ES2601820T3 (es) | 2007-02-23 | 2017-02-16 | Gilead Sciences, Inc. | Moduladores de propiedades terapéutica de las farmacocinéticas |
| SI2296633T1 (sl) * | 2008-05-02 | 2015-11-30 | Gilead Sciences, Inc. | Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva |
| CN101444494B (zh) * | 2008-12-31 | 2011-03-30 | 江苏大学 | 难溶性药物高效长效缓释制剂及其制法 |
| CN101444503B (zh) * | 2008-12-31 | 2011-02-02 | 江苏大学 | 一种水飞蓟宾高效长效制剂及其制法 |
| CN101439025B (zh) * | 2008-12-31 | 2011-05-11 | 江苏大学 | 一种水飞蓟素高效长效制剂及其制法 |
| CA2748496C (en) * | 2009-01-21 | 2019-02-26 | Mylan Inc. | Disintegrable formulations of lanthanum carbonate |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| SG10201500152UA (en) | 2009-12-22 | 2015-03-30 | Abbvie Inc | Abt-263 capsule |
| US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| RU2598345C2 (ru) | 2010-10-29 | 2016-09-20 | Эббви Инк. | Твердые дисперсии, содержащие средства, вызывающие апоптоз |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| BR112013012740A2 (pt) | 2010-11-23 | 2016-09-13 | Abbvie Inc | sais e formas cristalinas de um agente que induz apoptose |
| PT2642999T (pt) | 2010-11-23 | 2017-01-05 | Abbvie Ireland Unlimited Co | Métodos de tratamento que utilizam inibidores seletivos de bcl-2 |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| DE102011052396A1 (de) * | 2011-08-04 | 2013-02-07 | Gelita Ag | Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung |
| KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
| PE20141649A1 (es) | 2011-10-06 | 2014-11-14 | Novartis Ag | Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina |
| CN102793673A (zh) * | 2012-09-07 | 2012-11-28 | 中国药科大学 | 一种小檗碱磷脂复合物固体分散体及其制备方法 |
| EP2948134B1 (en) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TW201503912A (zh) * | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| KR20160084438A (ko) | 2013-11-13 | 2016-07-13 | 노파르티스 아게 | 면역 반응을 강화하기 위한 mTOR 억제제 |
| CN103610646B (zh) * | 2013-12-05 | 2015-07-15 | 江苏奥赛康药业股份有限公司 | 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| WO2016135740A1 (en) | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
| JP6857141B2 (ja) | 2015-05-20 | 2021-04-14 | ノバルティス アーゲー | エベロリムスとダクトリシブとの薬学的組合せ |
| US10383860B2 (en) | 2015-07-28 | 2019-08-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same |
| EP3466424A1 (en) * | 2016-05-27 | 2019-04-10 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprizing rapamycin or derivative thereof |
| EP4137132A1 (en) | 2016-09-30 | 2023-02-22 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
| CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
| IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| CN110831582B (zh) | 2017-07-05 | 2023-08-11 | 诺华股份有限公司 | 药物组合物 |
| CN108125918B (zh) * | 2018-01-12 | 2020-06-23 | 杭州中美华东制药有限公司 | 依维莫司药物组合物 |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| US5211958A (en) * | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US4920102A (en) | 1988-04-18 | 1990-04-24 | Eli Lilly And Company | Method for treating gastrointestinal disorders |
| IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
| CZ286958B6 (cs) | 1991-07-03 | 2000-08-16 | Pharmacia & Upjohn Company | Tabletování lékových směsí hydrochloridu colestipolu |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| IL115742A (en) | 1994-10-26 | 2000-06-01 | Novartis Ag | Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant |
| FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| DE19549852B4 (de) | 1995-11-29 | 2009-06-04 | Novartis Ag | Cyclosporin enthaltende Präparate |
| ES2231369T3 (es) * | 1996-02-29 | 2005-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Granulo de disgregacion rapida de un edulcorante sintetico que contiene acido silicico y/o dioxido de silicio. |
| JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
| ES2188928T3 (es) * | 1996-04-26 | 2003-07-01 | Shionogi & Co | Pastilla de liberador-rapido s1452. |
| GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
| JP2001503766A (ja) * | 1996-11-12 | 2001-03-21 | フアーマシア・アンド・アツプジヨン・アー・ベー | 複数の多孔質セルロースマトリクス（ｐｃｍ）を含むコンパクト部材、その製造および使用方法 |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
| CN1133424C (zh) | 1997-06-13 | 2004-01-07 | 惠氏公司 | 口服给药的雷怕霉素制剂 |
| SI1064942T1 (en) | 1998-03-26 | 2004-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparation of a macrolide |
| FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
| GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| WO2000054752A1 (fr) * | 1999-03-15 | 2000-09-21 | Kaken Pharmaceutical Co., Ltd. | Comprimes a delitement rapide et procede de fabrication |
| FR2793690B1 (fr) | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
| PT1179342E (pt) * | 1999-05-21 | 2006-07-31 | Kissei Pharmaceutical | Composicoes medicinais de libertacao imediata para utilizacao oral |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| CN101128189A (zh) | 2005-02-25 | 2008-02-20 | 弗·哈夫曼-拉罗切有限公司 | 药物物质分散性改善的片剂 |
| TWI347942B (en) | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
-
2001
- 2001-09-28 GB GBGB0123400.4A patent/GB0123400D0/en not_active Ceased
-
2002
- 2002-09-26 PE PE2002000948A patent/PE20030602A1/es not_active Application Discontinuation
- 2002-09-26 EC EC2002004323A patent/ECSP024323A/es unknown
- 2002-09-26 AR ARP020103642A patent/AR036643A1/es not_active Application Discontinuation
- 2002-09-27 HU HU0402394A patent/HU229991B1/hu unknown
- 2002-09-27 MX MXPA04002814A patent/MXPA04002814A/es active IP Right Grant
- 2002-09-27 PT PT91778894T patent/PT2193788E/pt unknown
- 2002-09-27 DK DK02774661.9T patent/DK1432408T3/da active
- 2002-09-27 JP JP2003532038A patent/JP2005507897A/ja not_active Withdrawn
- 2002-09-27 DK DK09177889.4T patent/DK2193788T3/en active
- 2002-09-27 NZ NZ542273A patent/NZ542273A/en not_active IP Right Cessation
- 2002-09-27 CN CN2006101159063A patent/CN1951390B/zh not_active Expired - Lifetime
- 2002-09-27 SI SI200230928T patent/SI1432408T1/sl unknown
- 2002-09-27 AT AT02774661T patent/ATE485813T1/de active
- 2002-09-27 IL IL16049802A patent/IL160498A0/xx unknown
- 2002-09-27 CO CO02087099A patent/CO5390072A1/es not_active Application Discontinuation
- 2002-09-27 BR BR0212922-1A patent/BR0212922A/pt not_active IP Right Cessation
- 2002-09-27 EP EP02774661A patent/EP1432408B8/en not_active Expired - Lifetime
- 2002-09-27 CN CN2010101174089A patent/CN101912392A/zh active Pending
- 2002-09-27 NZ NZ531599A patent/NZ531599A/en not_active IP Right Cessation
- 2002-09-27 CA CA2458455A patent/CA2458455C/en not_active Expired - Lifetime
- 2002-09-27 RU RU2004113205/15A patent/RU2322970C2/ru active
- 2002-09-27 KR KR1020047004628A patent/KR100626785B1/ko active IP Right Grant
- 2002-09-27 BR BRPI0212922-1A patent/BRPI0212922B1/pt unknown
- 2002-09-27 EP EP09177889.4A patent/EP2193788B1/en not_active Expired - Lifetime
- 2002-09-27 US US10/490,089 patent/US20040254210A1/en not_active Abandoned
- 2002-09-27 CN CNA028190459A patent/CN1561201A/zh active Pending
- 2002-09-27 PT PT02774661T patent/PT1432408E/pt unknown
- 2002-09-27 ES ES09177889.4T patent/ES2560106T3/es not_active Expired - Lifetime
- 2002-09-27 WO PCT/EP2002/010890 patent/WO2003028705A1/en active Search and Examination
- 2002-09-27 ES ES02774661T patent/ES2354687T3/es not_active Expired - Lifetime
- 2002-09-27 PL PL367896A patent/PL209704B1/pl not_active IP Right Cessation
- 2002-09-27 MY MYPI20023631A patent/MY150060A/en unknown
- 2002-09-27 DE DE60238131T patent/DE60238131D1/de not_active Expired - Lifetime
- 2002-09-27 TW TW091122345A patent/TWI242449B/zh not_active IP Right Cessation
-
2004
- 2004-02-18 ZA ZA200401300A patent/ZA200401300B/en unknown
- 2004-02-19 IL IL160498A patent/IL160498A/en active IP Right Grant
- 2004-03-26 NO NO20041270A patent/NO333892B1/no not_active IP Right Cessation
- 2004-12-15 HK HK10107727.3A patent/HK1141239A1/xx not_active IP Right Cessation
- 2004-12-15 HK HK04109968.5A patent/HK1067036A1/xx not_active IP Right Cessation
-
2008
- 2008-12-04 JP JP2008309431A patent/JP5160386B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-10 US US12/776,711 patent/US20100221331A1/en not_active Abandoned
- 2010-11-30 CY CY20101101091T patent/CY1111119T1/el unknown
-
2011
- 2011-06-13 US US13/158,921 patent/US20110306630A1/en not_active Abandoned
-
2012
- 2012-06-05 US US13/489,396 patent/US8617598B2/en not_active Expired - Lifetime
-
2014
- 2014-08-14 AR ARP140103055A patent/AR097341A2/es unknown
-
2016
- 2016-01-21 CY CY20161100068T patent/CY1117164T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009102341A5 (ja) | ||
| JP2005507897A5 (ja) | ||
| AR097341A2 (es) | Composición farmaceutica que comprende una dispersión de macrólidos sólidos, y un proceso para producir una tableta dispersable que contiene un macrólido | |
| WO2009074351A3 (en) | Solid forms of tenofovir disoproxil | |
| WO2011049706A8 (en) | Orally transformable tablets | |
| WO2009043844A3 (en) | Orodispersible tablets | |
| WO2004100857A3 (en) | Highly plastic granules for making fast melting tablets | |
| NZ610729A (en) | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate | |
| WO2006128121A3 (en) | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | |
| TW200621268A (en) | Antimicrobial copolymers and uses thereof | |
| IL192374A0 (en) | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol | |
| NZ592325A (en) | Extended release oral acetaminophen/tramadol dosage form | |
| JP2009280621A5 (ja) | ||
| MX2008012731A (es) | Tabletas de paracetamol de liberacion rapida. | |
| NZ610701A (en) | Once daily formulation of lacosamide | |
| MX343358B (es) | Tabletas de acetato de ulipristal. | |
| JP2011518842A5 (ja) | ||
| EP1980272A3 (en) | Orally-disintegrating tablet and manufacturing method thereof | |
| TW200637537A (en) | Pharmaceutical composition containing sibutramine free base and manufacturing method thereof | |
| WO2011053003A3 (en) | Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer | |
| IL207928A (en) | Pharmacotherapeutic agent that contains an active drug (mtx) and helps 2, 2-anhydropyrimidine to reduce and use mtx toxicity | |
| HRP20100120T1 (hr) | Formulacije s valsartanom | |
| GEP20125636B (en) | Slow-release formulation based on glycogen and alginate association | |
| WO2011141791A3 (en) | Extended release formulations of desvenlafaxine base | |
| IL179859A0 (en) | Oral sustained release formulation of tedisamil with gastric retention properties |